Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PRS-343 |
Trade Name | |
Synonyms | |
Drug Descriptions |
PRS-343 is a bispecific antibody targeting both CD137 (4-1BB) and Erbb2 (Her2), resulting in enhanced anti-tumor immune response against Erbb2 (Her2)-positive tumor cells (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301, PMID: 31138587). |
DrugClasses | HER2 (ERBB2) Antibody 76 TNFRSF9 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C142890 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + PRS-343 | Atezolizumab PRS-343 | 0 | 1 |
Paclitaxel + PRS-343 + Ramucirumab | PRS-343 Paclitaxel Ramucirumab | 0 | 1 |
PRS-343 | PRS-343 | 0 | 1 |
PRS-343 + Tucatinib | PRS-343 Tucatinib | 0 | 1 |